Section of Respiratory Medicine, Dept of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
Division of Respiratory Medicine and Allergy, Karolinska University Hospital Solna, Stockholm, Sweden.
Eur Respir Rev. 2018 Feb 7;27(147). doi: 10.1183/16000617.0076-2017. Print 2018 Mar 31.
Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.
最佳支持治疗(BSC)通常被定义为旨在改善和优化受进展性疾病影响的患者生活质量(QoL)的所有干预措施和多专业方法。从这个意义上说,它排除了可能直接针对疾病的其他干预措施,或者与之互补。BSC 可提高多种癌症患者的生存率。特发性肺纤维化(IPF)患者在疾病的自然病程中会经历广泛的症状,BSC 干预可能会产生有益的效果。这篇综述强调了目前针对 QoL 干预措施的证据,以及在 IPF 患者的治疗中对 BSC 进行临床评估的空白。目前只有少数改善 QoL 或控制症状的干预措施得到了精心设计的研究的支持。在评估 IPF 中的 BSC 时,方法学必须合理,并且必须使用经过验证的工具来测量这一特定患者群体的 QoL 和症状控制。